Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis

Conor C. Murphy, Kathrin Greiner, Jarka Plskova, N. Andrew Frost, John V. Forrester, Andrew D. Dick

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aim: To evaluate the responsiveness of the Vision core module 1 ( VCM1) vision-related quality of life ( VR-QOL) questionnaire to changes in visual acuity in patients with posterior and intermediate uveitis and to validate its use as a clinical end point in uveitis.

Methods: Logarithm of the minimum angle of resolution visual acuity and VR-QOL using the VCM1 questionnaire were prospectively recorded in 37 patients with active posterior segment intraocular inflammation before starting systemic immunosuppression with ciclosporin, tacrolimus or the antitumour necrosis factor ( TNF) agent, p55TNFr-Ig, and again 3 months later. Spearman analysis was used to correlate improvements in visual acuity and VR-QOL between baseline and 3 months.

Results: The correlation between changes in visual acuity and VR-QOL was moderate to good for the worse eye ( r = 0.47, p = 0.003), but poor for the better eye ( r = -0.05, p = 0.91). The responsiveness indices effect size and standardised response mean were 0.57 and 0.59, respectively, showing that the VCM1 questionnaire is moderately responsive to immunsosuppressive therapy for active uveitis.

Conclusion: Changes in VR-QOL measured with the VCM1 questionnaire correlated moderately well with changes in the worse eye visual acuity, suggesting that the VCM1 is a valid instrument for monitoring response to treatment in uveitis.

Original languageEnglish
Pages (from-to)154-156
Number of pages3
JournalBritish Journal of Ophthalmology
Volume91
Issue number2
Early online date14 Sep 2006
DOIs
Publication statusPublished - Feb 2007

Keywords

  • visual function
  • general health
  • therapy

Cite this

Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. / Murphy, Conor C.; Greiner, Kathrin; Plskova, Jarka; Frost, N. Andrew; Forrester, John V.; Dick, Andrew D.

In: British Journal of Ophthalmology, Vol. 91, No. 2, 02.2007, p. 154-156.

Research output: Contribution to journalArticle

Murphy, Conor C. ; Greiner, Kathrin ; Plskova, Jarka ; Frost, N. Andrew ; Forrester, John V. ; Dick, Andrew D. / Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. In: British Journal of Ophthalmology. 2007 ; Vol. 91, No. 2. pp. 154-156.
@article{cdff7379a31e471aa1d8f6591d0321f0,
title = "Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis",
abstract = "Aim: To evaluate the responsiveness of the Vision core module 1 ( VCM1) vision-related quality of life ( VR-QOL) questionnaire to changes in visual acuity in patients with posterior and intermediate uveitis and to validate its use as a clinical end point in uveitis.Methods: Logarithm of the minimum angle of resolution visual acuity and VR-QOL using the VCM1 questionnaire were prospectively recorded in 37 patients with active posterior segment intraocular inflammation before starting systemic immunosuppression with ciclosporin, tacrolimus or the antitumour necrosis factor ( TNF) agent, p55TNFr-Ig, and again 3 months later. Spearman analysis was used to correlate improvements in visual acuity and VR-QOL between baseline and 3 months.Results: The correlation between changes in visual acuity and VR-QOL was moderate to good for the worse eye ( r = 0.47, p = 0.003), but poor for the better eye ( r = -0.05, p = 0.91). The responsiveness indices effect size and standardised response mean were 0.57 and 0.59, respectively, showing that the VCM1 questionnaire is moderately responsive to immunsosuppressive therapy for active uveitis.Conclusion: Changes in VR-QOL measured with the VCM1 questionnaire correlated moderately well with changes in the worse eye visual acuity, suggesting that the VCM1 is a valid instrument for monitoring response to treatment in uveitis.",
keywords = "visual function, general health, therapy",
author = "Murphy, {Conor C.} and Kathrin Greiner and Jarka Plskova and Frost, {N. Andrew} and Forrester, {John V.} and Dick, {Andrew D.}",
year = "2007",
month = "2",
doi = "10.1136/bjo.2006.105528",
language = "English",
volume = "91",
pages = "154--156",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis

AU - Murphy, Conor C.

AU - Greiner, Kathrin

AU - Plskova, Jarka

AU - Frost, N. Andrew

AU - Forrester, John V.

AU - Dick, Andrew D.

PY - 2007/2

Y1 - 2007/2

N2 - Aim: To evaluate the responsiveness of the Vision core module 1 ( VCM1) vision-related quality of life ( VR-QOL) questionnaire to changes in visual acuity in patients with posterior and intermediate uveitis and to validate its use as a clinical end point in uveitis.Methods: Logarithm of the minimum angle of resolution visual acuity and VR-QOL using the VCM1 questionnaire were prospectively recorded in 37 patients with active posterior segment intraocular inflammation before starting systemic immunosuppression with ciclosporin, tacrolimus or the antitumour necrosis factor ( TNF) agent, p55TNFr-Ig, and again 3 months later. Spearman analysis was used to correlate improvements in visual acuity and VR-QOL between baseline and 3 months.Results: The correlation between changes in visual acuity and VR-QOL was moderate to good for the worse eye ( r = 0.47, p = 0.003), but poor for the better eye ( r = -0.05, p = 0.91). The responsiveness indices effect size and standardised response mean were 0.57 and 0.59, respectively, showing that the VCM1 questionnaire is moderately responsive to immunsosuppressive therapy for active uveitis.Conclusion: Changes in VR-QOL measured with the VCM1 questionnaire correlated moderately well with changes in the worse eye visual acuity, suggesting that the VCM1 is a valid instrument for monitoring response to treatment in uveitis.

AB - Aim: To evaluate the responsiveness of the Vision core module 1 ( VCM1) vision-related quality of life ( VR-QOL) questionnaire to changes in visual acuity in patients with posterior and intermediate uveitis and to validate its use as a clinical end point in uveitis.Methods: Logarithm of the minimum angle of resolution visual acuity and VR-QOL using the VCM1 questionnaire were prospectively recorded in 37 patients with active posterior segment intraocular inflammation before starting systemic immunosuppression with ciclosporin, tacrolimus or the antitumour necrosis factor ( TNF) agent, p55TNFr-Ig, and again 3 months later. Spearman analysis was used to correlate improvements in visual acuity and VR-QOL between baseline and 3 months.Results: The correlation between changes in visual acuity and VR-QOL was moderate to good for the worse eye ( r = 0.47, p = 0.003), but poor for the better eye ( r = -0.05, p = 0.91). The responsiveness indices effect size and standardised response mean were 0.57 and 0.59, respectively, showing that the VCM1 questionnaire is moderately responsive to immunsosuppressive therapy for active uveitis.Conclusion: Changes in VR-QOL measured with the VCM1 questionnaire correlated moderately well with changes in the worse eye visual acuity, suggesting that the VCM1 is a valid instrument for monitoring response to treatment in uveitis.

KW - visual function

KW - general health

KW - therapy

U2 - 10.1136/bjo.2006.105528

DO - 10.1136/bjo.2006.105528

M3 - Article

VL - 91

SP - 154

EP - 156

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 2

ER -